Biomarker Selection And Measurement In Neurodegenerative Clinical Trials

Neurodegenerative diseases, a class of conditions characterized by progressive neuronal degeneration, pose a significant challenge to global healthcare. These disorders, including Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), Amyotrophic Lateral Sclerosis (ALS), and Multiple Sclerosis (MS), are associated with diverse and debilitating symptoms. To advance our understanding and treatment of these diseases, researchers have focused on identifying biomarkers that can aid in early diagnosis, predict disease progression, and evaluate the efficacy of therapeutic interventions.

By reading this paper, you will learn the critical role of protein biomarkers in neurodegenerative diseases by examining their clinicopathologic correlations and strategies for their clinical measurement. These insights are key to advancing our understanding of neurodegenerative disease progression and informing the development of effective therapeutic interventions.